Azacyclic ethynyl derivatives
Azacyclic ethynyl derivatives, which are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.
1. An azacyclic ethynyl derivative represented by Formula III:
or an enantiomer or a mixture of its enantiomers or a pharmaceutically acceptable salt thereof, wherein
n is 1;
L is absent and
X represents a phenyl group, which phenyl is optionally substituted one or two times with alkyl, cycloalkyl, alkoxy, cycloalkoxy, halogen, CF 3 , OCF 3 , cyano, amino, or nitro; or a cyclohex-1-enyl group; a cyclohexa-1,3-dienyl group; a cyclohept-1-enyl group; or a cyclohepta-1,3-dienyl group.
2. The azacyclic ethynyl derivative of claim 1 , which is
(±)-3-phenylethynyl-quinuclidin-2-ene
(±)-1-methyl-3-phenylethynyl-quinuclidin-2-ene; or
(±)-3-(1-cyclohexenylethynyl)-quinuclidine-2-ene;
or an enantiomer or a mixture of its enantiomers, or a pharmaceutically acceptable salt thereof.
3. A pharmaceutical composition comprising a therapeutically effective amount of an azacyclic ethynyl derivative of claim 1 , or an enantiomer or a mixture of its enantiomers, or a pharmaceutically-acceptable addition salt thereof, together with at least one pharmaceutically-acceptable carrier or diluent.
4. The compound of claim 2 , which is
(±)-3-phenylethynyl-quinuclidin-2-ene,
or an enantiomer or a mixture of its enantiomers, or a pharmaceutically acceptable salt thereof.